Synovial cell production of IL-26 induces bone mineralization in spondyloarthritis

Spondyloarthritis (SpA) is characterized by inflammation and new bone formation and can be treated by inhibition of the proinflammatory cytokines TNF-α and IL-17A. IL-26 is considered a proinflammatory cytokine, predominantly related to Th17 cells. In the present study, we investigate IL-26 expressi...

Full description

Saved in:
Bibliographic Details
Published inJournal of molecular medicine (Berlin, Germany) Vol. 95; no. 7; pp. 779 - 787
Main Authors Heftdal, Line Dam, Andersen, Thomas, Jæhger, Ditte, Woetmann, Anders, Østgård, René, Kenngott, Elisabeth E., Syrbe, Uta, Sieper, Joachim, Hvid, Malene, Deleuran, Bent, Kragstrup, Tue W.
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 01.07.2017
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN0946-2716
1432-1440
1432-1440
DOI10.1007/s00109-017-1528-2

Cover

Loading…
Abstract Spondyloarthritis (SpA) is characterized by inflammation and new bone formation and can be treated by inhibition of the proinflammatory cytokines TNF-α and IL-17A. IL-26 is considered a proinflammatory cytokine, predominantly related to Th17 cells. In the present study, we investigate IL-26 expression in SpA patients, and examine the in vitro production of IL-26 by synovial cells and the effects of IL-26 on human osteoblasts. IL-26 was measured by ELISA in plasma and synovial fluid (SF) of 15 SpA patients and in plasma samples from 12 healthy controls. Facet joints from axial SpA patients were stained for IL-26 and analyzed by fluorescence microscopy. Synovial fluid mononuclear cells, C-C motif chemokine receptor 6 memory Th17 cells, and fibroblast-like synoviocytes (FLSs) were isolated, and supernatants were analyzed for IL-26 content by ELISA. FLSs were further stained for IL-26 production and the myofibroblast marker α-smooth-muscle-actin (αSMA) and analyzed by flow cytometry. Human osteoblasts were cultured in the presence of IL-26, and the degree of mineralization was quantified. We found that IL-26 levels in SF were increased compared with plasma ( P  < 0.0001). Moreover, IL-26 expression was found in facet joints of axial SpA patients within the bone marrow. IL-26 secretion was primarily found in αSMA + myofibroblasts. In contrast, Th17 cells did not produce detectable amounts of IL-26. Human osteoblasts treated with IL-26 showed increased mineralization compared with untreated osteoblasts ( P  = 0.02). In conclusion, IL-26 seems to be produced by myofibroblasts in the inflamed synovium and could be a possible facilitator of bone mineralization in SpA. Key messages IL-26 levels are higher in synovial fluid compared to plasma in spondyloarthritis. IL-26 was identified in axial facet joints of spondyloarthritis patients. Myofibroblasts from the spondyloarthritis synovium produce large amounts of IL-26. IL-26 induces bone mineralization in human osteoblasts.
AbstractList Spondyloarthritis (SpA) is characterized by inflammation and new bone formation and can be treated by inhibition of the proinflammatory cytokines TNF-α and IL-17A. IL-26 is considered a proinflammatory cytokine, predominantly related to Th17 cells. In the present study, we investigate IL-26 expression in SpA patients, and examine the in vitro production of IL-26 by synovial cells and the effects of IL-26 on human osteoblasts. IL-26 was measured by ELISA in plasma and synovial fluid (SF) of 15 SpA patients and in plasma samples from 12 healthy controls. Facet joints from axial SpA patients were stained for IL-26 and analyzed by fluorescence microscopy. Synovial fluid mononuclear cells, C-C motif chemokine receptor 6 memory Th17 cells, and fibroblast-like synoviocytes (FLSs) were isolated, and supernatants were analyzed for IL-26 content by ELISA. FLSs were further stained for IL-26 production and the myofibroblast marker α-smooth-muscle-actin (αSMA) and analyzed by flow cytometry. Human osteoblasts were cultured in the presence of IL-26, and the degree of mineralization was quantified. We found that IL-26 levels in SF were increased compared with plasma (P < 0.0001). Moreover, IL-26 expression was found in facet joints of axial SpA patients within the bone marrow. IL-26 secretion was primarily found in αSMA+ myofibroblasts. In contrast, Th17 cells did not produce detectable amounts of IL-26. Human osteoblasts treated with IL-26 showed increased mineralization compared with untreated osteoblasts (P = 0.02). In conclusion, IL-26 seems to be produced by myofibroblasts in the inflamed synovium and could be a possible facilitator of bone mineralization in SpA.Spondyloarthritis (SpA) is characterized by inflammation and new bone formation and can be treated by inhibition of the proinflammatory cytokines TNF-α and IL-17A. IL-26 is considered a proinflammatory cytokine, predominantly related to Th17 cells. In the present study, we investigate IL-26 expression in SpA patients, and examine the in vitro production of IL-26 by synovial cells and the effects of IL-26 on human osteoblasts. IL-26 was measured by ELISA in plasma and synovial fluid (SF) of 15 SpA patients and in plasma samples from 12 healthy controls. Facet joints from axial SpA patients were stained for IL-26 and analyzed by fluorescence microscopy. Synovial fluid mononuclear cells, C-C motif chemokine receptor 6 memory Th17 cells, and fibroblast-like synoviocytes (FLSs) were isolated, and supernatants were analyzed for IL-26 content by ELISA. FLSs were further stained for IL-26 production and the myofibroblast marker α-smooth-muscle-actin (αSMA) and analyzed by flow cytometry. Human osteoblasts were cultured in the presence of IL-26, and the degree of mineralization was quantified. We found that IL-26 levels in SF were increased compared with plasma (P < 0.0001). Moreover, IL-26 expression was found in facet joints of axial SpA patients within the bone marrow. IL-26 secretion was primarily found in αSMA+ myofibroblasts. In contrast, Th17 cells did not produce detectable amounts of IL-26. Human osteoblasts treated with IL-26 showed increased mineralization compared with untreated osteoblasts (P = 0.02). In conclusion, IL-26 seems to be produced by myofibroblasts in the inflamed synovium and could be a possible facilitator of bone mineralization in SpA.IL-26 levels are higher in synovial fluid compared to plasma in spondyloarthritis. IL-26 was identified in axial facet joints of spondyloarthritis patients. Myofibroblasts from the spondyloarthritis synovium produce large amounts of IL-26. IL-26 induces bone mineralization in human osteoblasts.KEY MESSAGESIL-26 levels are higher in synovial fluid compared to plasma in spondyloarthritis. IL-26 was identified in axial facet joints of spondyloarthritis patients. Myofibroblasts from the spondyloarthritis synovium produce large amounts of IL-26. IL-26 induces bone mineralization in human osteoblasts.
Spondyloarthritis (SpA) is characterized by inflammation and new bone formation and can be treated by inhibition of the proinflammatory cytokines TNF-α and IL-17A. IL-26 is considered a proinflammatory cytokine, predominantly related to Th17 cells. In the present study, we investigate IL-26 expression in SpA patients, and examine the in vitro production of IL-26 by synovial cells and the effects of IL-26 on human osteoblasts. IL-26 was measured by ELISA in plasma and synovial fluid (SF) of 15 SpA patients and in plasma samples from 12 healthy controls. Facet joints from axial SpA patients were stained for IL-26 and analyzed by fluorescence microscopy. Synovial fluid mononuclear cells, C-C motif chemokine receptor 6 memory Th17 cells, and fibroblast-like synoviocytes (FLSs) were isolated, and supernatants were analyzed for IL-26 content by ELISA. FLSs were further stained for IL-26 production and the myofibroblast marker α-smooth-muscle-actin (αSMA) and analyzed by flow cytometry. Human osteoblasts were cultured in the presence of IL-26, and the degree of mineralization was quantified. We found that IL-26 levels in SF were increased compared with plasma (P < 0.0001). Moreover, IL-26 expression was found in facet joints of axial SpA patients within the bone marrow. IL-26 secretion was primarily found in αSMA myofibroblasts. In contrast, Th17 cells did not produce detectable amounts of IL-26. Human osteoblasts treated with IL-26 showed increased mineralization compared with untreated osteoblasts (P = 0.02). In conclusion, IL-26 seems to be produced by myofibroblasts in the inflamed synovium and could be a possible facilitator of bone mineralization in SpA. IL-26 levels are higher in synovial fluid compared to plasma in spondyloarthritis. IL-26 was identified in axial facet joints of spondyloarthritis patients. Myofibroblasts from the spondyloarthritis synovium produce large amounts of IL-26. IL-26 induces bone mineralization in human osteoblasts.
Spondyloarthritis (SpA) is characterized by inflammation and new bone formation and can be treated by inhibition of the proinflammatory cytokines TNF-α and IL-17A. IL-26 is considered a proinflammatory cytokine, predominantly related to Th17 cells. In the present study, we investigate IL-26 expression in SpA patients, and examine the in vitro production of IL-26 by synovial cells and the effects of IL-26 on human osteoblasts. IL-26 was measured by ELISA in plasma and synovial fluid (SF) of 15 SpA patients and in plasma samples from 12 healthy controls. Facet joints from axial SpA patients were stained for IL-26 and analyzed by fluorescence microscopy. Synovial fluid mononuclear cells, C-C motif chemokine receptor 6 memory Th17 cells, and fibroblast-like synoviocytes (FLSs) were isolated, and supernatants were analyzed for IL-26 content by ELISA. FLSs were further stained for IL-26 production and the myofibroblast marker α-smooth-muscle-actin (αSMA) and analyzed by flow cytometry. Human osteoblasts were cultured in the presence of IL-26, and the degree of mineralization was quantified. We found that IL-26 levels in SF were increased compared with plasma ( P  < 0.0001). Moreover, IL-26 expression was found in facet joints of axial SpA patients within the bone marrow. IL-26 secretion was primarily found in αSMA + myofibroblasts. In contrast, Th17 cells did not produce detectable amounts of IL-26. Human osteoblasts treated with IL-26 showed increased mineralization compared with untreated osteoblasts ( P  = 0.02). In conclusion, IL-26 seems to be produced by myofibroblasts in the inflamed synovium and could be a possible facilitator of bone mineralization in SpA. Key messages IL-26 levels are higher in synovial fluid compared to plasma in spondyloarthritis. IL-26 was identified in axial facet joints of spondyloarthritis patients. Myofibroblasts from the spondyloarthritis synovium produce large amounts of IL-26. IL-26 induces bone mineralization in human osteoblasts.
Abstract Spondyloarthritis (SpA) is characterized by inflammation and new bone formation and can be treated by inhibition of the proinflammatory cytokines TNF-[alpha] and IL-17A. IL-26 is considered a proinflammatory cytokine, predominantly related to Th17 cells. In the present study, we investigate IL-26 expression in SpA patients, and examine the in vitro production of IL-26 by synovial cells and the effects of IL-26 on human osteoblasts. IL-26 was measured by ELISA in plasma and synovial fluid (SF) of 15 SpA patients and in plasma samples from 12 healthy controls. Facet joints from axial SpA patients were stained for IL-26 and analyzed by fluorescence microscopy. Synovial fluid mononuclear cells, C-C motif chemokine receptor 6 memory Th17 cells, and fibroblast-like synoviocytes (FLSs) were isolated, and supernatants were analyzed for IL-26 content by ELISA. FLSs were further stained for IL-26 production and the myofibroblast marker [alpha]-smooth-muscle-actin ([alpha]SMA) and analyzed by flow cytometry. Human osteoblasts were cultured in the presence of IL-26, and the degree of mineralization was quantified. We found that IL-26 levels in SF were increased compared with plasma (P < 0.0001). Moreover, IL-26 expression was found in facet joints of axial SpA patients within the bone marrow. IL-26 secretion was primarily found in [alpha]SMA+ myofibroblasts. In contrast, Th17 cells did not produce detectable amounts of IL-26. Human osteoblasts treated with IL-26 showed increased mineralization compared with untreated osteoblasts (P = 0.02). In conclusion, IL-26 seems to be produced by myofibroblasts in the inflamed synovium and could be a possible facilitator of bone mineralization in SpA. Key messages IL-26 levels are higher in synovial fluid compared to plasma in spondyloarthritis. IL-26 was identified in axial facet joints of spondyloarthritis patients. Myofibroblasts from the spondyloarthritis synovium produce large amounts of IL-26. IL-26 induces bone mineralization in human osteoblasts.
Author Hvid, Malene
Jæhger, Ditte
Kenngott, Elisabeth E.
Woetmann, Anders
Østgård, René
Syrbe, Uta
Deleuran, Bent
Sieper, Joachim
Kragstrup, Tue W.
Heftdal, Line Dam
Andersen, Thomas
Author_xml – sequence: 1
  givenname: Line Dam
  surname: Heftdal
  fullname: Heftdal, Line Dam
  organization: Department of Biomedicine, Aarhus University
– sequence: 2
  givenname: Thomas
  surname: Andersen
  fullname: Andersen, Thomas
  organization: Department of Biomedicine, Aarhus University, Department of Rheumatology, Aarhus University Hospital
– sequence: 3
  givenname: Ditte
  surname: Jæhger
  fullname: Jæhger, Ditte
  organization: Department of Immunology and Microbiology, University of Copenhagen
– sequence: 4
  givenname: Anders
  surname: Woetmann
  fullname: Woetmann, Anders
  organization: Department of Immunology and Microbiology, University of Copenhagen
– sequence: 5
  givenname: René
  surname: Østgård
  fullname: Østgård, René
  organization: Department of Rheumatology, Regional Hospital Silkeborg
– sequence: 6
  givenname: Elisabeth E.
  surname: Kenngott
  fullname: Kenngott, Elisabeth E.
  organization: Department of Gastroenterology, Infectiology, and Rheumatology, Charité Universitätsmedizin Berlin
– sequence: 7
  givenname: Uta
  surname: Syrbe
  fullname: Syrbe, Uta
  organization: Department of Gastroenterology, Infectiology, and Rheumatology, Charité Universitätsmedizin Berlin
– sequence: 8
  givenname: Joachim
  surname: Sieper
  fullname: Sieper, Joachim
  organization: Department of Gastroenterology, Infectiology, and Rheumatology, Charité Universitätsmedizin Berlin
– sequence: 9
  givenname: Malene
  surname: Hvid
  fullname: Hvid, Malene
  organization: Department of Biomedicine, Aarhus University, Department of Clinical Medicine, Aarhus University
– sequence: 10
  givenname: Bent
  surname: Deleuran
  fullname: Deleuran, Bent
  email: bd@biomed.au.dk
  organization: Department of Biomedicine, Aarhus University, Department of Rheumatology, Aarhus University Hospital, Department of Clinical Medicine, Aarhus University
– sequence: 11
  givenname: Tue W.
  surname: Kragstrup
  fullname: Kragstrup, Tue W.
  organization: Department of Biomedicine, Aarhus University, Department of Rheumatology, Aarhus University Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28365787$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtr3DAUhUVJaSZpf0A2wZBNN2qvXpa0DKGPwEChj7XQ2NeNgkeaSHZh-usrZxIogWQlEN85OjrnhBzFFJGQMwYfGID-WAAYWApMU6a4ofwVWTEpOGVSwhFZgZUt5Zq1x-SklNtKa2XlG3LMjWiVNnpFvv_Yx_Qn-LHpcBybXU793E0hxSYNzfWa8rYJsV5haTb18WYbImY_hr_-HgqxKbsU-_2YfJ5ucphCeUteD34s-O7hPCW_Pn_6efWVrr99ub66XNNOCjPRASzazvdgOgUcea9bJTqve9goBAHSDpZvjLG2RxRacmwHVIJx1WpQkotT8v7gW0PfzVgmtw1l-YWPmObimDHCSADeVvTiCXqb5hxrOscsAy5qe4vh-QM1b7bYu10OW5_37rGtCugD0OVUSsbBdWG6L2LKPoyOgVt2cYddXK3bLbu4xZo9UT6av6ThB02pbPyN-b_Qz4r-ASNmnXk
CitedBy_id crossref_primary_10_1080_19420862_2019_1654305
crossref_primary_10_3389_fmed_2021_700982
crossref_primary_10_3389_fimmu_2022_1077914
crossref_primary_10_3389_fimmu_2021_663192
crossref_primary_10_1016_j_bbrc_2018_04_004
crossref_primary_10_1186_s13075_019_2070_0
crossref_primary_10_1186_s41927_019_0093_4
crossref_primary_10_1016_j_jtauto_2025_100266
crossref_primary_10_3390_jpm12101685
crossref_primary_10_3389_fimmu_2019_00204
crossref_primary_10_1016_j_jid_2023_10_038
crossref_primary_10_3389_fimmu_2024_1355824
crossref_primary_10_3389_fimmu_2018_02226
crossref_primary_10_1007_s00281_021_00837_0
crossref_primary_10_1186_s41927_018_0040_9
crossref_primary_10_2119_molmed_2016_00064
crossref_primary_10_1016_j_ejr_2023_04_002
crossref_primary_10_1016_j_semarthrit_2022_152159
crossref_primary_10_1098_rsos_180528
crossref_primary_10_3389_fmicb_2021_757215
crossref_primary_10_1177_1759720X19828669
Cites_doi 10.4049/jimmunol.172.4.2006
10.1586/eci.10.49
10.1016/j.jbspin.2004.02.010
10.1016/S0092-8674(01)00187-8
10.1136/annrheumdis-2011-200859
10.1371/journal.pbio.1001395
10.1016/S0140-6736(11)60071-8
10.1007/s40265-016-0598-8
10.1186/2193-1801-2-263
10.1186/ar4471
10.1038/nm.3218
10.1074/jbc.M405000200
10.1007/s10067-015-2961-7
10.1002/cyto.a.22995
10.4049/jimmunol.168.11.5397
10.2217/imt.15.93
10.1111/imm.12142
10.1186/ar3370
10.1002/art.37704
10.1056/NEJMoa1505066
10.1007/s00393-014-1394-z
10.1111/j.1582-4934.2009.00984.x
10.1002/art.39805
10.1186/ar2642
10.1164/rccm.201404-0689OC
10.1038/srep24339
10.1159/000434646
10.1002/14651858.CD005468.pub2
10.1002/art.37703
ContentType Journal Article
Copyright Springer-Verlag Berlin Heidelberg 2017
Journal of Molecular Medicine is a copyright of Springer, 2017.
Copyright_xml – notice: Springer-Verlag Berlin Heidelberg 2017
– notice: Journal of Molecular Medicine is a copyright of Springer, 2017.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TK
7X7
7XB
88E
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1007/s00109-017-1528-2
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central - New (Subscription)
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

ProQuest One Academic Middle East (New)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1432-1440
EndPage 787
ExternalDocumentID 28365787
10_1007_s00109_017_1528_2
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Novo Nordisk Fonden
– fundername: Gigtforeningen
  funderid: http://dx.doi.org/10.13039/100008368
GroupedDBID ---
-4W
-56
-5G
-BR
-EM
-Y2
-~C
.55
.86
.VR
06C
06D
0R~
0VY
199
1N0
2.D
203
28-
29L
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
36B
3O-
3SX
3V.
4.4
406
408
409
40D
40E
53G
5GY
5QI
5RE
5VS
67N
67Z
6NX
78A
7X7
88E
8AO
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABJNI
ABJOX
ABKCH
ABKTR
ABLJU
ABMNI
ABMQK
ABNWP
ABOCM
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTHY
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHXU
ACIWK
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACZOJ
ADBBV
ADHIR
ADIMF
ADINQ
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADYPR
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFEXP
AFGCZ
AFKRA
AFLOW
AFQWF
AFRAH
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AOCGG
ARMRJ
ASPBG
AXYYD
AZFZN
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BPHCQ
BSONS
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
EBD
EBLON
EBS
EIOEI
EJD
EMB
EMOBN
EN4
EPAXT
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GXS
H13
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
LAS
LLZTM
M1P
M4Y
MA-
N2Q
N9A
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
P19
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R89
R9I
RHV
RIG
RNI
RNS
ROL
RPX
RRX
RSV
RZK
S16
S1Z
S26
S27
S28
S3A
S3B
SAP
SBL
SBY
SCLPG
SDH
SDM
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZN
T13
T16
TSG
TSK
TSV
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK6
WK8
X7M
YLTOR
Z45
Z7R
Z7U
Z7W
Z7Z
Z82
Z83
Z87
Z8M
Z8O
Z8Q
Z8T
Z8V
Z8W
Z91
ZMTXR
ZOVNA
~EX
AAPKM
AAYXX
ABBRH
ABDBE
ADHKG
AFDZB
AFOHR
AGQPQ
AHPBZ
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
7TK
7XB
8FK
ABRTQ
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
ID FETCH-LOGICAL-c438t-f09e9cad08c502e2d7653ca7d0b5e03049f92b8899dee3742e6fe531256705423
IEDL.DBID 7X7
ISSN 0946-2716
1432-1440
IngestDate Fri Jul 11 15:32:54 EDT 2025
Sat Aug 16 08:02:20 EDT 2025
Wed Feb 19 02:32:30 EST 2025
Tue Jul 01 02:55:35 EDT 2025
Thu Apr 24 22:56:49 EDT 2025
Fri Feb 21 02:25:55 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords Fibroblasts
IL-26
TNF-α
Spondyloarthritis
Osteoblasts
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c438t-f09e9cad08c502e2d7653ca7d0b5e03049f92b8899dee3742e6fe531256705423
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 28365787
PQID 1910235282
PQPubID 48876
PageCount 9
ParticipantIDs proquest_miscellaneous_1883840026
proquest_journals_1910235282
pubmed_primary_28365787
crossref_citationtrail_10_1007_s00109_017_1528_2
crossref_primary_10_1007_s00109_017_1528_2
springer_journals_10_1007_s00109_017_1528_2
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-07-01
PublicationDateYYYYMMDD 2017-07-01
PublicationDate_xml – month: 07
  year: 2017
  text: 2017-07-01
  day: 01
PublicationDecade 2010
PublicationPlace Berlin/Heidelberg
PublicationPlace_xml – name: Berlin/Heidelberg
– name: Germany
– name: New York
PublicationTitle Journal of molecular medicine (Berlin, Germany)
PublicationTitleAbbrev J Mol Med
PublicationTitleAlternate J Mol Med (Berl)
PublicationYear 2017
Publisher Springer Berlin Heidelberg
Springer Nature B.V
Publisher_xml – name: Springer Berlin Heidelberg
– name: Springer Nature B.V
References Shah, Perry, Deodhar (CR30) 2015; 7
Andersen, Al-Karradi, Kragstrup, Hokland (CR26) 2016; 89
Yang, Yuan, Miao, Xu (CR3) 2015; 74
Appel, Maier, Wu, Scheer, Hempfing, Kayser, Thiel, Radbruch, Loddenkemper, Sieper (CR23) 2011; 13
Deodhar, Dougados, Baeten, Wei, Geusens, Readie, Richards, Martin, Porter (CR7) 2016
CR19
CR15
Wolk, Kunz, Asadullah, Sabat (CR14) 2002; 168
Stebulis, Rossetti, Atez, Zurier (CR25) 2005; 32
Hor, Pirzer, Dumoutier, Bauer, Wittmann, Sticht, Renauld, de Waal, Fickenscher (CR18) 2004; 279
Sheikh, Baurin, Lewis-Antes, Shah, Smirnov, Anantha, Dickensheets, Dumoutier, Renauld, Zdanov (CR17) 2004; 172
Raychaudhuri, Saxena, Raychaudhuri (CR10) 2015; 34
Kragstrup, Jalilian, Hvid, Kjærgaard, Østgård, Schiøttz-Christensen, Jurik, Robinson, Vorup-Jensen, Deleuran (CR24) 2014; 16
CR6
CR5
Dougados, Baeten (CR1) 2011; 377
CR27
LeBleu, Taduri, O’Connell, Teng, Cooke, Woda, Sugimoto, Kalluri (CR12) 2013; 19
Claudepierre, Voisin (CR2) 2005; 72
CR21
Blair, Dhillon (CR9) 2016; 76
Yeremenko, Noordenbos, Cantaert, van Tok, van de Sande, Cañete, Tak, Baeten (CR13) 2012; 65
Baeten, Sieper, Braun, Baraliakos, Dougados, Emery, Deodhar, Porter, Martin, Andersson (CR8) 2015; 373
Maksymowych, Morency, Conner-Spady, Lambert (CR4) 2013; 72
Kragstrup, Vorup-Jensen, Deleuran, Hvid (CR22) 2013; 2
Kirkham, Kavanaugh, Reich (CR11) 2014; 141
Voulgari (CR28) 2010; 6
Corvaisier, Delneste, Jeanvoine, Preisser, Blanchard, Garo, Hoppe, Barré, Audran, Bouvard (CR16) 2012; 10
Blumberg, Conklin, Xu, Grossmann, Brender, Carollo, Eagan, Foster, Haldeman, Hammond (CR20) 2001; 104
Milia, Ibba-Manneschi, Manetti, Benelli, Generini, Messerini, Matucci-Cerinic (CR29) 2011; 15
WP Maksymowych (1528_CR4) 2013; 72
F Sheikh (1528_CR17) 2004; 172
1528_CR6
S Hor (1528_CR18) 2004; 279
1528_CR5
TW Kragstrup (1528_CR24) 2014; 16
N Yeremenko (1528_CR13) 2012; 65
M Corvaisier (1528_CR16) 2012; 10
SK Raychaudhuri (1528_CR10) 2015; 34
1528_CR15
M Yang (1528_CR3) 2015; 74
1528_CR19
TW Kragstrup (1528_CR22) 2013; 2
M Dougados (1528_CR1) 2011; 377
HA Blair (1528_CR9) 2016; 76
H Appel (1528_CR23) 2011; 13
K Wolk (1528_CR14) 2002; 168
H Blumberg (1528_CR20) 2001; 104
PV Voulgari (1528_CR28) 2010; 6
VS LeBleu (1528_CR12) 2013; 19
R Shah (1528_CR30) 2015; 7
A Deodhar (1528_CR7) 2016
JA Stebulis (1528_CR25) 2005; 32
1528_CR27
MN Andersen (1528_CR26) 2016; 89
D Baeten (1528_CR8) 2015; 373
BW Kirkham (1528_CR11) 2014; 141
1528_CR21
P Claudepierre (1528_CR2) 2005; 72
AF Milia (1528_CR29) 2011; 15
References_xml – volume: 172
  start-page: 2006
  year: 2004
  end-page: 2010
  ident: CR17
  article-title: Cutting edge: IL-26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-10 receptor 2
  publication-title: J Immunol
  doi: 10.4049/jimmunol.172.4.2006
– volume: 6
  start-page: 721
  year: 2010
  end-page: 733
  ident: CR28
  article-title: Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
  publication-title: Expert Rev Clin Immunol
  doi: 10.1586/eci.10.49
– volume: 72
  start-page: 32
  year: 2005
  end-page: 37
  ident: CR2
  article-title: The entheses: histology, pathology, and pathophysiology
  publication-title: Joint Bone Spine
  doi: 10.1016/j.jbspin.2004.02.010
– volume: 104
  start-page: 9
  year: 2001
  end-page: 19
  ident: CR20
  article-title: Interleukin 20: discovery, receptor identification, and role in epidermal function
  publication-title: Cell
  doi: 10.1016/S0092-8674(01)00187-8
– ident: CR6
– volume: 72
  start-page: 23
  year: 2013
  end-page: 28
  ident: CR4
  article-title: Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2011-200859
– volume: 10
  start-page: e1001395
  year: 2012
  end-page: e1001315
  ident: CR16
  article-title: IL-26 is overexpressed in rheumatoid arthritis and induces proinflammatory cytokine production and Th17 cell generation
  publication-title: PLoS Biol
  doi: 10.1371/journal.pbio.1001395
– volume: 377
  start-page: 2127
  year: 2011
  end-page: 2137
  ident: CR1
  article-title: Spondyloarthritis
  publication-title: Lancet
  doi: 10.1016/S0140-6736(11)60071-8
– ident: CR27
– volume: 76
  start-page: 1023
  year: 2016
  end-page: 1030
  ident: CR9
  article-title: Secukinumab: a review in ankylosing spondylitis
  publication-title: Drugs
  doi: 10.1007/s40265-016-0598-8
– volume: 2
  start-page: 263
  year: 2013
  ident: CR22
  article-title: A simple set of validation steps identifies and removes false results in a sandwich enzyme-linked immunosorbent assay caused by anti-animal IgG antibodies in plasma from arthritis patients
  publication-title: Spring
  doi: 10.1186/2193-1801-2-263
– volume: 16
  start-page: R42
  year: 2014
  end-page: R15
  ident: CR24
  article-title: Decreased plasma levels of soluble CD18 link leukocyte infiltration with disease activity in spondyloarthritis
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar4471
– ident: CR21
– ident: CR19
– volume: 19
  start-page: 1047
  year: 2013
  end-page: 1053
  ident: CR12
  article-title: Origin and function of myofibroblasts in kidney fibrosis
  publication-title: Nat Med
  doi: 10.1038/nm.3218
– ident: CR15
– year: 2016
  ident: CR7
  article-title: Effect of secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis: a phase 3 randomized trial (MEASURE 1)
  publication-title: Arthritis Rheumatol
– volume: 279
  start-page: 33343
  year: 2004
  end-page: 33351
  ident: CR18
  article-title: The T-cell lymphokine interleukin-26 targets epithelial cells through the interleukin-20 receptor 1 and interleukin-10 receptor 2 chains
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M405000200
– volume: 34
  start-page: 1019
  year: 2015
  end-page: 1023
  ident: CR10
  article-title: Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis
  publication-title: Clin Rheumatol
  doi: 10.1007/s10067-015-2961-7
– volume: 89
  start-page: 1001
  year: 2016
  end-page: 1009
  ident: CR26
  article-title: Elimination of erroneous results in flow cytometry caused by antibody binding to Fc receptors on human monocytes and macrophages
  publication-title: Cytometry A
  doi: 10.1002/cyto.a.22995
– volume: 168
  start-page: 5397
  year: 2002
  end-page: 5402
  ident: CR14
  article-title: Cutting edge: immune cells as sources and targets of the IL-10 family members?
  publication-title: J Immunol
  doi: 10.4049/jimmunol.168.11.5397
– ident: CR5
– volume: 7
  start-page: 1241
  year: 2015
  end-page: 1247
  ident: CR30
  article-title: The role of secukinumab in the treatment of ankylosing spondylitis
  publication-title: Immunotherapy
  doi: 10.2217/imt.15.93
– volume: 141
  start-page: 133
  year: 2014
  end-page: 142
  ident: CR11
  article-title: Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis
  publication-title: Immunology
  doi: 10.1111/imm.12142
– volume: 13
  start-page: R95
  year: 2011
  ident: CR23
  article-title: Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar3370
– volume: 65
  start-page: 174
  year: 2012
  end-page: 185
  ident: CR13
  article-title: Disease-specific and inflammation-independent stromal alterations in spondylarthritis synovitis
  publication-title: Arthritis & Rheum
  doi: 10.1002/art.37704
– volume: 32
  start-page: 301
  year: 2005
  end-page: 306
  ident: CR25
  article-title: Fibroblast-like synovial cells derived from synovial fluid
  publication-title: J Rheumatol
– volume: 373
  start-page: 2534
  year: 2015
  end-page: 2548
  ident: CR8
  article-title: Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1505066
– volume: 74
  start-page: 340
  year: 2015
  end-page: 345
  ident: CR3
  article-title: Größeres osteogenes Potenzial von ligamentären Fibroblasten bei Patienten mit Spondylitis ankylosans als bei Patienten mit Arthrose
  publication-title: Z Rheumatol
  doi: 10.1007/s00393-014-1394-z
– volume: 15
  start-page: 270
  year: 2011
  end-page: 279
  ident: CR29
  article-title: Evidence for the prevention of enthesitis in HLA-B27/hβ(2)m transgenic rats treated with a monoclonal antibody against TNF-α
  publication-title: J Cell Mol Med
  doi: 10.1111/j.1582-4934.2009.00984.x
– volume: 104
  start-page: 9
  year: 2001
  ident: 1528_CR20
  publication-title: Cell
  doi: 10.1016/S0092-8674(01)00187-8
– volume: 89
  start-page: 1001
  year: 2016
  ident: 1528_CR26
  publication-title: Cytometry A
  doi: 10.1002/cyto.a.22995
– year: 2016
  ident: 1528_CR7
  publication-title: Arthritis Rheumatol
  doi: 10.1002/art.39805
– volume: 6
  start-page: 721
  year: 2010
  ident: 1528_CR28
  publication-title: Expert Rev Clin Immunol
  doi: 10.1586/eci.10.49
– volume: 72
  start-page: 23
  year: 2013
  ident: 1528_CR4
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2011-200859
– volume: 7
  start-page: 1241
  year: 2015
  ident: 1528_CR30
  publication-title: Immunotherapy
  doi: 10.2217/imt.15.93
– volume: 34
  start-page: 1019
  year: 2015
  ident: 1528_CR10
  publication-title: Clin Rheumatol
  doi: 10.1007/s10067-015-2961-7
– volume: 74
  start-page: 340
  year: 2015
  ident: 1528_CR3
  publication-title: Z Rheumatol
  doi: 10.1007/s00393-014-1394-z
– ident: 1528_CR5
  doi: 10.1186/ar2642
– volume: 19
  start-page: 1047
  year: 2013
  ident: 1528_CR12
  publication-title: Nat Med
  doi: 10.1038/nm.3218
– volume: 2
  start-page: 263
  year: 2013
  ident: 1528_CR22
  publication-title: Spring
  doi: 10.1186/2193-1801-2-263
– volume: 13
  start-page: R95
  year: 2011
  ident: 1528_CR23
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar3370
– ident: 1528_CR15
  doi: 10.1164/rccm.201404-0689OC
– volume: 76
  start-page: 1023
  year: 2016
  ident: 1528_CR9
  publication-title: Drugs
  doi: 10.1007/s40265-016-0598-8
– volume: 141
  start-page: 133
  year: 2014
  ident: 1528_CR11
  publication-title: Immunology
  doi: 10.1111/imm.12142
– volume: 15
  start-page: 270
  year: 2011
  ident: 1528_CR29
  publication-title: J Cell Mol Med
  doi: 10.1111/j.1582-4934.2009.00984.x
– volume: 377
  start-page: 2127
  year: 2011
  ident: 1528_CR1
  publication-title: Lancet
  doi: 10.1016/S0140-6736(11)60071-8
– volume: 279
  start-page: 33343
  year: 2004
  ident: 1528_CR18
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M405000200
– volume: 32
  start-page: 301
  year: 2005
  ident: 1528_CR25
  publication-title: J Rheumatol
– ident: 1528_CR21
  doi: 10.1038/srep24339
– volume: 10
  start-page: e1001395
  year: 2012
  ident: 1528_CR16
  publication-title: PLoS Biol
  doi: 10.1371/journal.pbio.1001395
– volume: 172
  start-page: 2006
  year: 2004
  ident: 1528_CR17
  publication-title: J Immunol
  doi: 10.4049/jimmunol.172.4.2006
– volume: 65
  start-page: 174
  year: 2012
  ident: 1528_CR13
  publication-title: Arthritis & Rheum
  doi: 10.1002/art.37704
– volume: 72
  start-page: 32
  year: 2005
  ident: 1528_CR2
  publication-title: Joint Bone Spine
  doi: 10.1016/j.jbspin.2004.02.010
– volume: 373
  start-page: 2534
  year: 2015
  ident: 1528_CR8
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1505066
– ident: 1528_CR19
  doi: 10.1159/000434646
– ident: 1528_CR27
  doi: 10.1002/14651858.CD005468.pub2
– volume: 168
  start-page: 5397
  year: 2002
  ident: 1528_CR14
  publication-title: J Immunol
  doi: 10.4049/jimmunol.168.11.5397
– volume: 16
  start-page: R42
  year: 2014
  ident: 1528_CR24
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar4471
– ident: 1528_CR6
  doi: 10.1002/art.37703
SSID ssj0017594
Score 2.3238323
Snippet Spondyloarthritis (SpA) is characterized by inflammation and new bone formation and can be treated by inhibition of the proinflammatory cytokines TNF-α and...
Abstract Spondyloarthritis (SpA) is characterized by inflammation and new bone formation and can be treated by inhibition of the proinflammatory cytokines...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 779
SubjectTerms Actin
Adult
Aged
Arthritis
Biomedical and Life Sciences
Biomedicine
Bone marrow
Cells, Cultured
Enzyme-linked immunosorbent assay
Female
Fibroblasts - immunology
Fibroblasts - pathology
Flow cytometry
Helper cells
Human Genetics
Humans
Inflammation
Inflammatory diseases
Interleukins - analysis
Interleukins - blood
Interleukins - immunology
Internal Medicine
Joint diseases
Leukocytes (mononuclear)
Lymphocytes T
Male
Middle Aged
Mineralization
Molecular Medicine
Original Article
Osteoblasts
Osteoblasts - immunology
Osteoblasts - pathology
Osteogenesis
Plasma
Rheumatic diseases
Secretion
Smooth muscle
Spondylarthritis - blood
Spondylarthritis - immunology
Spondylarthritis - pathology
Synovial fluid
Synovial Fluid - cytology
Synovial Fluid - immunology
Synoviocytes
Synoviocytes - immunology
Synoviocytes - pathology
Synovium
Th17 Cells - immunology
Th17 Cells - pathology
Tumor necrosis factor
Tumor Necrosis Factor-alpha - immunology
Vitamin D
Young Adult
SummonAdditionalLinks – databaseName: SpringerLink Journals (ICM)
  dbid: U2A
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1dS8MwFL3oBPFF_LY6JYJPSqBL27R9HKJMcT6og72VNk1R0G64TfDfe5K1RZkKPjdNw_3IPac3uZfoVGYScUFIDizkc3ii5qZBEvcDoYRQgAA20d6_k72BfzMMhtU97kl92r1OSdqdurnsZrM43OyqiDlQ7zKtBIa6w4gHotukDsLAdj8EbZFcgA3UqcyfpvgejBYQ5kJ21Aadqw1ar9Ai687Vu0lLutyi1X6VD9-m-4ePcvQOE2LmBzwbz8u3QtRsVLDrWy4kA-eG9iYsG5WavT7bItPV3Us8Y-aEbA7SDgt6svWNdmhwdfl40eNVlwSufC-a8sKNdazS3I1U4Aot8lAGnkrD3M0CbRKfcRGLLAKvyrX2wIS1LDQ8D1gnBF4T3i61Sixhn1ioQAA72pV5J_ZTcKfcS_0cClSRW0SqcMitxZWoqoS46WTxkjTFj62EE0g4MRJOhENnzSvjef2Mvwa3ax0klStNEhBKU5MH1NChk-YxnMAINi31aIYxUeSBqYJPOrQ3113zNeAnabYlh85rZX6Z_LelHPxr9CGtCWNV9hhvm1rTt5k-AliZZsfWOD8BH7jcIQ
  priority: 102
  providerName: Springer Nature
Title Synovial cell production of IL-26 induces bone mineralization in spondyloarthritis
URI https://link.springer.com/article/10.1007/s00109-017-1528-2
https://www.ncbi.nlm.nih.gov/pubmed/28365787
https://www.proquest.com/docview/1910235282
https://www.proquest.com/docview/1883840026
Volume 95
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS9xAEB9ahdIX0dqP-MUWfLIszW2STfIkp5y1rUqxPbg-hWR3QwVNTu8U_O_97d4mtkh9CuRzmZndmd_O5DdEu7KS8AtCcsRCMcdMNNw2SOJxIpQQCiGAS7Sfnsnjcfxtkkz8htvMl1V2a6JbqHWr7B75Z-AKS80ChLA_vea2a5TNrvoWGi9p2VKX2ZKudNIDLnhG1wgRCEZyAWDQZTVDRyI6cJVCKYcHg7H865eeBJtPEqXO_xyt0ooPHNlwoek1emGaN_Tq1KfG1-n8533T3sGamN2LZ9MFkyukztqafT3hQjLAbyhyxqq2MezqwvFN-98wcY3ZYlkN_A5j-uOojt7S-Gj06_CY-4YJXMVRNud1mJtclTrMVBIKI3Qqk0iVqQ6rxNgcaF7nosoAsbQxEUCxkbXBJETYkyJ0E9E7WmowhA_EUgUsODCh1IM8LgGjdFTGGrpUWVhnqg4o7MRVKM8mbptaXBY9D7KTcAEJF1bChQhor39kuqDSeO7mrU4HhZ9Vs-LRBgL62F_GfLCCLRvT3uKeLIsAWgEtA3q_0F3_NYRS0q5QAX3qlPnXy_83lI3nh7JJr4U1I1fCu0VL85tbs41AZV7tOGvcoeXhl9_fRzgejM5-nOPsWAwfAKWL47M
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Nb9QwEB1VWwm4oPIdWqiR4AKyyDqJkxwQAtpql-6uUGml3kJiOwKpJEt3W7R_it_Is_MBVdXeeo6TWDPP9jyP_YbopSwk1gUhOWKhkGMkGm4LJPEwEkoIhRDAJdqnMzk6Cj8fR8dr9Ke7C2OPVXZzopuoda3sHvlb8AorzQKG8H7-i9uqUTa72pXQaGCxb1a_QdkW78Y78O8rIfZ2Dz-NeFtVgKswSJa89FOTqlz7iYp8YYSOZRSoPNZ-ERmbKEzLVBQJeIg2JgBzNLI0QCpigxjxjRU6wJS_HgagMgNa_7g7-3LQ5y3iyJVeBGeSXICKdHlU38mWDt3ZpJhjzQQ8L66El8LbS6lZt-LtbdDdNlRlHxps3aM1U92nW9M2Gf-ADr6uqvoc-GV295_NG-1Y-JnVJRtPuJAMhB_QWbCirgz7-cMpXLcXP_GM2eO5enVSA77fnbjSQzq6EWM-okGFLjwhFiuwz6HxpR6mYQ7ipoM81ECPSvwyUaVHfmeuTLX65baMxknWKy87C2ewcGYtnAmPXvevzBvxjusab3U-yNpxvMj-oc6jF_1jjEBr2Lwy9RnaJEkAmgwy69Hjxnf93xC8STsnevSmc-Z_H7-qK0-v78o23R4dTifZZDzb36Q7wkLKHSDeosHy9Mw8Q5i0LJ632GT07aaHw19Efhyy
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LT9wwEB4hkFAvVQt9hNJipPbSyiLrJE5yQFUFrNjyUNUWaW9pYjsCiSbb7gLav9Zf18_OAxCCG-e8rJlvPPNlxjNE72Uh4ReE5IiFQg5LNNwOSOJhJJQQCiGAS7QfHcv9k_DrOBov0L_uLIwtq-z2RLdR61rZf-Rb4BW2NQsYwlbZlkV82x1-nvzhdoKUzbR24zQaiByY-RXo23R7tAtdfxBiuPdzZ5-3Ewa4CoNkxks_NanKtZ-oyBdG6FhGgcpj7ReRsUnDtExFkYCTaGMCsEgjSwPUIk6IEevYpgfY_pfiIBpYG4vHPdmDV3ZDGMGeJBcgJV1G1XcNTAeuSinm8J4A6m2feCfQvZOkdb5v-IyetkEr-9Kg7DktmGqFlo_atPwqff8xr-pLIJnZPACbNF1koXFWl2x0yIVkoP4A0ZQVdWXY7zPX67o9AoprzBbq6vl5DSCfujZLL-jkUUT5khYrLOE1sViBhw6ML_UgDXNQOB3koQaOVOKXiSo98jtxZartZG4HapxnfQ9mJ-EMEs6shDPh0cf-kUnTxuOhm9c7HWStRU-za_x5tNlfhi1aweaVqS9wT5IEIMygtR69anTXfw1hnLS7o0efOmXeePl9S1l7eCkbtAwjyA5Hxwdv6ImwiHKVxOu0OPt7Yd4iXpoV7xwwGf16bEv4D8ZoH4I
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Synovial+cell+production+of+IL-26+induces+bone+mineralization+in+spondyloarthritis&rft.jtitle=Journal+of+molecular+medicine+%28Berlin%2C+Germany%29&rft.au=Heftdal%2C+Line+Dam&rft.au=Andersen%2C+Thomas&rft.au=J%C3%A6hger%2C+Ditte&rft.au=Woetmann%2C+Anders&rft.date=2017-07-01&rft.pub=Springer+Nature+B.V&rft.issn=0946-2716&rft.eissn=1432-1440&rft.volume=95&rft.issue=7&rft.spage=779&rft_id=info:doi/10.1007%2Fs00109-017-1528-2&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0946-2716&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0946-2716&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0946-2716&client=summon